ACS patients in the PLATO trial who received the investigational antiplatelet agent ticagrelor (AstraZeneca) and then underwent CABG were 50% less likely to die than those who received clopidogrel. But this difference in mortality was not explained by bleeding events, which were similar between the two drug arms.

Join moderator Dr Tony Gershlick and his guests Drs Peter Berger and Timothy Gardner as they tease out the implications for cardiologists and surgeons of these important findings and take a look at the STICH and CSP-474 results presented at the ACC 2010 Scientific Sessions.